Baidu
map

J Allergy Clin Immunol:300°IR舌下片是一种有效的、安全的治疗屋尘螨引起的过敏性鼻炎的方法

2020-10-02 AlexYang MedSci原创

最近,有研究人员评估了屋尘螨:粉尘满 1:1提取物的300反应指数(IR)舌下片剂在中度至重度HDM诱导AR的青少年(年龄≥12岁)和成人中的疗效和安全性情况。

最近,有研究人员评估了屋尘螨:粉尘满 1:1提取物的300反应指数(IR)舌下片剂在中度至重度HDM诱导AR的青少年(年龄≥12岁)和成人中的疗效和安全性情况。

在一项III期、国际、双盲、安慰剂对照、随机临床试验中,参与者接受安慰剂或300°IR片剂治疗约12个月。研究人员将1607名参与者随机分配,其中1476人(包括555人(37.6%)在入选时伴有轻度可控哮喘)组成完整的分析集。研究发现,在主要评价期内,300°IR组的最小二乘平均aTCS(3.62)显著低于安慰剂组(4.35)(P<0.0001),相对最小二乘平均差异为-16.9%[95%CI:-24.0%;-9.2%]。相对于安慰剂组,300°IR组所有预设的次要终点均得到持续改善。另外,300°IR片总体上耐受性良好。治疗相关的不良事件(主要是轻度或中度的局部反应)在300°IR片组有51.0%的患者出现,安慰剂组有14.9%的患者出现。

最后,研究人员指出,300°IR舌下含服HDM片是一种有效、安全的治疗HDM诱发的AR的方法。

原始出处:

Pascal Demoly, Jonathan Corren , Peter Creticos et al. A 300°IR sublingual tablet is an effective, safe treatment for house-dust-mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized Phase III clinical trial. J Allergy Clin Immunol. Sep 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047313, encodeId=d1c3204e31378, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Mar 17 16:49:48 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329422, encodeId=37031329422ac, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Oct 04 08:49:48 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348599, encodeId=9cbd13485993b, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Oct 04 08:49:48 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047313, encodeId=d1c3204e31378, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Mar 17 16:49:48 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329422, encodeId=37031329422ac, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Oct 04 08:49:48 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348599, encodeId=9cbd13485993b, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Oct 04 08:49:48 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
    2020-10-04 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047313, encodeId=d1c3204e31378, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Mar 17 16:49:48 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329422, encodeId=37031329422ac, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Oct 04 08:49:48 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348599, encodeId=9cbd13485993b, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Oct 04 08:49:48 CST 2020, time=2020-10-04, status=1, ipAttribution=)]

相关资讯

Int Arch Allergy Immunol:过敏性鼻炎儿童特异性舌下免疫治疗安全性的风险因素研究

良好的依从性往往归因于舌下免疫疗法(SLIT)的良好疗效和安全性。然而,很少有关于儿童SLIT治疗安全性的研究。

Pediatr Allergy Immunol:儿童变应性鼻炎皮下和舌下免疫治疗方法对比,它们的依从性、有效性和安全性分别如何?

尽管之前的研究已经证实了皮下免疫治疗(SCIT)和舌下免疫治疗(SLIT)的有效性和安全性,但直接对SCIT与SLIT进行的正面比较甚少。在近期发表在Pediatr Allergy Immunol期刊

Immunotherapy:微晶酪氨酸相关螨虫提取物免疫疗法治疗过敏性鼻炎的安全性和有效性

最近,有研究人员评估了一种微晶酪氨酸相关螨虫过敏原免疫疗法(AIT)在现实世界过敏性鼻炎(AR)患者治疗中的安全性和有效性情况。

于金明:肿瘤免疫治疗十大挑战

肿瘤内科治疗进展的三次革命,依次为以细胞周期为主的化疗,以基因突变为主的靶向药物,以免疫逃逸为主的免疫治疗。免疫治疗在非小细胞肺癌治疗中是全程不可或缺的,但也面临着十大现实挑战。

Nat Commun :颠覆认知!免疫力强并非好事?研究发现更强大的免疫系统可能会阻碍癌症的免疫治疗

众所周知,化疗、手术等传统的治疗方法,主要利用外力来消灭肿瘤。而免疫治疗,则是通过增强患者自身的免疫应答来抑制肿瘤生长。疾病的发生和免疫力有关,普遍认为免疫力越强,治疗癌症的效果就越好。

免疫治疗头颈部鳞癌一线长生存数据公布

免疫治疗作为近年来肿瘤治疗领域的超级新星,获批的适应证已经覆盖了十余种实体瘤和血液肿瘤。在近期举行的欧洲肿瘤内科学会(ESMO)上,免疫治疗更是大放异彩,公布了多项重磅研究长期随访结果。这无疑显示出了

Baidu
map
Baidu
map
Baidu
map